The stock of SeaSpine Holdings Corporation (NASDAQ:SPNE) last traded at $9.54, up 8.29% from the previous session.
SPNE stock price is now 34.71% away from the 50-day moving average and 27.76% away from the 200-day moving average. The market capitalization of the company currently stands at $360.18M.
With the price target reduced from $12 to $6.75, Truist Downgraded its rating from Buy to Hold for SeaSpine Holdings Corporation (NASDAQ: SPNE). , while ‘Truist’ rates the stock as ‘Buy’.
In other news, Maniar Shweta, Director sold 3,786 shares of the company’s stock on Dec 29. The stock was sold for $30,288 at an average price of $8.00. Upon completion of the transaction, the Director now directly owns 23,993 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 14, President, Enabling Tech Standish Beau sold 50,000 shares of the business’s stock. A total of $286,500 was realized by selling the stock at an average price of $5.73. A total of 9.65% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SPNE stock. In total, there are 148 active investors with 72.72% ownership of the company’s stock.
With an opening price of $8.83 on Friday morning, SeaSpine Holdings Corporation (NASDAQ: SPNE) set off the trading day. During the past 12 months, SeaSpine Holdings Corporation has had a low of $5.48 and a high of $14.23. The fifty day moving average price for SPNE is $7.27 and a two-hundred day moving average price translates $7.31 for the stock.
The latest earnings results from SeaSpine Holdings Corporation (NASDAQ: SPNE) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.35 by -0.03. This compares to -$0.48 EPS in the same period last year. The company reported revenue of $67.15 million for the quarter, compared to $46.45 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 44.57 percent. For the current quarter, analysts expect SPNE to generate $65.68M in revenue.
SeaSpine Holdings Corporation(SPNE) Company Profile
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. It offers orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. The company’s orthobiologics products include demineralized bone matrix (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. It also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. In addition, the company offers implant products for spinal decompression, alignment, stabilization, and image-guided surgical solutions, as well as a surgical navigation system used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.